Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 421 to 430 of 1532

TitleReference numberPublishedLast updated
Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancerTA816
Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrenceTA817
SecurAcath for securing percutaneous cathetersMTG34
Stockholm3 for prostate cancer screeningMIB303
Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancerTA812
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitorsTA813
Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitisTA814
Bioresorbable stent implantation to treat coronary artery diseaseIPG732
Aortic remodelling hybrid stent insertion during surgical repair of an acute type A aortic dissectionIPG733
Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal)TA811

Results per page

  1. 10
  2. 25
  3. 50
  4. All